- $165.24bn
- $227.87bn
- $58.50bn
- 57
- 60
- 94
- 80
Pfizer Inc - Pfizer Completes Acquisition of Rights to Exubera
AnnouncementRule 2.10 Announcement
AnnouncementPfizer Inc - Lipitor Significantly Reduced hsCRP Levels in Patients with Stable
AnnouncementPfizer Inc - Pfizer Receives Approvable Letter From FDA For Maraviroc
AnnouncementPfizer Inc - Pfizer Discontinues Clinical Trials for PF-3512676 Combined with Cy
AnnouncementPfizer Inc - Pfizer on Track to Deliver Greater Shareholder Value, CEO Kindler T
AnnouncementPfizer Inc - Pfizer Invites Public to View and Listen to Webcast of Pfizer Prese
AnnouncementPfizer Inc - Pfizer Discontinues One Sunitinib Phase 3 Trial in Advanced Breast
AnnouncementPfizer Inc Pfizers Lyrica Receives Complete Response Letter From FDA For Genera
AnnouncementPfizer Inc Pfizer Reports First-Quarter 2009
AnnouncementPfizer Inc - Pfizer Discontinues Global Phase III Trial of Axitinib for Futility
AnnouncementRule 2.10 Announcement
AnnouncementPfizer Inc - Regulatory Approval
AnnouncementPfizer Inc - Pfizer Animal Health Enters into Agreement to Acquire Animal Health
AnnouncementPfizer Inc - Pfizer Animal Health Enters into Agreement to Acquire Animal Health
AnnouncementPfizer Inc - Pfizer Animal Health Enters into Agreement to Acquire Animal Health
AnnouncementPfizer Inc - Statement re Lipitor
AnnouncementPfizer Inc - 3rd Quarter Results
AnnouncementRule 2.10 Announcement
Announcement